CompanyGraph
EL.En. S.p.A.
ELN · Borsa Italiana · Italy
Price data from its EE5 listing on XSTU
elengroup.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.35B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.95: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.64%Below 5Y avg (1.68%)
Annual Rate
EUR 0.25Paid annual
Payout Ratio
33.0%Sustainable
Payback Period
60.7 yr
Last Ex-Dividend
May 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.16BEUR1.35B · vs all stocks (USD)
Trailing P/E
22.61xvs Medical Devices peers
Revenue (TTM)
595.51MEUR695.71M · vs all stocks (USD)
Profit Margin
7.91%vs Medical Devices peers
Beta
1.07xvs all stocks
52-Week Change
26.17%vs all stocks
Market Capitalization
1.16BEUR1.35B · vs all stocks (USD)
Enterprise Value
222.17MEUR259.56M · vs all stocks (USD)
Trailing P/E
22.61xvs Medical Devices peers
Forward P/E
17.95xvs Medical Devices peers
PEG Ratio
1.01xvs Medical Devices peers
Price to Sales (TTM)
2.04xvs Medical Devices peers
Price to Book (MRQ)
2.95xvs Medical Devices peers
Enterprise to Revenue
0.3730xvs Medical Devices peers
Enterprise to EBITDA
2.65xvs Medical Devices peers
Gross Margin
45.54%vs Medical Devices peers
Profit Margin
7.91%vs Medical Devices peers
Operating Margin
10.81%vs Medical Devices peers
Return on Assets (TTM)
6.91%vs Medical Devices peers
Return on Equity (TTM)
12.99%vs Medical Devices peers
Revenue (TTM)
595.51MEUR695.71M · vs all stocks (USD)
Revenue per Share (TTM)
7.35EURUpdated Aug 21, 2026Quarterly Revenue Growth
24.80%vs Medical Devices peers
Gross Profit (TTM)
258.58MEUR302.08M · vs all stocks (USD)
EBITDA (TTM)
82.64MEUR96.55M · vs all stocks (USD)
Net Income (TTM)
53.68MEUR62.71M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-4.80%vs Medical Devices peers
Operating Cash Flow (TTM)
70.81MEUR82.73M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
43.42MEUR50.72M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2500EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.64%vs all stocks
5-Year Average Dividend Yield
1.68%vs all stocks
Payout Ratio
33.04%vs Medical Devices peers
Minority Interest (Equity)
15.32MEURFY2025 · Dec 31, 2025Revenue
590.85MEURFY2025 · Dec 31, 2025Cost of Goods Sold
337.15MEURFY2025 · Dec 31, 2025Gross Profit
253.70MEURFY2025 · Dec 31, 2025Operating Income
72.18MEUR84.32M · vs all stocks (USD)
Pre-tax Income
74.25MEURFY2025 · Dec 31, 2025Income Tax Expense
23.50MEURFY2025 · Dec 31, 2025Net Income
44.18MEURFY2025 · Dec 31, 2025EBIT
75.12MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
84.37MEURFY2025 · Dec 31, 2025Selling, General & Administrative
24.31MEURFY2025 · Dec 31, 2025Other Operating Expenses
36.47MEURFY2025 · Dec 31, 2025Non-operating Interest Income
2.49MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
860.69KEURFY2025 · Dec 31, 2025EPS (Basic)
0.5417EURFY2025 · Dec 31, 2025EPS (Diluted)
0.5417EURFY2025 · Dec 31, 2025Basic Shares Outstanding
80.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
80.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
44.18MEURFY2025 · Dec 31, 2025Minority Interests (P&L)
-769.63KEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
75.14MEURFY2025 · Dec 31, 2025Free Cash Flow
64.41MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
174.36MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
44.18MEURFY2025 · Dec 31, 2025Stock-based Compensation
2.16MEURFY2025 · Dec 31, 2025Other Non-cash Items
-10.05KEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.60MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
35.41MEURFY2025 · Dec 31, 2025Capital Expenditures
-10.74MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-839.11KEURFY2025 · Dec 31, 2025Net Acquisitions
28.13MEURFY2025 · Dec 31, 2025Other Investing Activity
645.48KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
18.04MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-1.58MEURFY2025 · Dec 31, 2025Common Stock Repurchase
-2.37MEURFY2025 · Dec 31, 2025Common Dividends Paid
-18.72MEURFY2025 · Dec 31, 2025Other Financing Charges
700.52KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-21.14MEURFY2025 · Dec 31, 2025Shares Outstanding
80.14MSharesUpdated Aug 21, 2026Float Shares
10.14MSharesUpdated Aug 21, 2026% Held by Insiders
41.90%vs all stocks
% Held by Institutions
30.08%vs all stocks
Total Cash (MRQ)
99.39MEUR116.11M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.15EURUpdated Aug 21, 2026Total Debt (MRQ)
15.04MEUR17.57M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0736xvs Medical Devices peers
Book Value per Share (MRQ)
5.14EURUpdated Aug 21, 2026Total Assets
627.88MEUR733.53M · vs all stocks (USD)
Total Current Assets
509.12MEURFY2025 · Dec 31, 2025Total Liabilities
200.41MEURFY2025 · Dec 31, 2025Total Non-current Assets
118.77MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
36.01MEURFY2025 · Dec 31, 2025Total Current Liabilities
164.39MEURFY2025 · Dec 31, 2025Cash
174.36MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
174.36MEURFY2025 · Dec 31, 2025Other Short-term Investments
37.08MEURFY2025 · Dec 31, 2025Accounts Receivable
117.34MEURFY2025 · Dec 31, 2025Inventory
157.26MEURFY2025 · Dec 31, 2025Accounts Payable
88.76MEURFY2025 · Dec 31, 2025Short-term Debt
20.76MEURFY2025 · Dec 31, 2025Other Current Liabilities
9.46MEURFY2025 · Dec 31, 2025Long-term Debt
17.30MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
689.39KEURFY2025 · Dec 31, 2025Common Stock (Book)
2.61MEURFY2025 · Dec 31, 2025Retained Earnings
221.91MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
427.47MEUR499.40M · vs all stocks (USD)
Treasury Stock
2.45MEURFY2025 · Dec 31, 202552-Week Low
10.34EURUpdated Aug 21, 202652-Week High
17.64EURUpdated Aug 21, 202652-Week Change
26.17%vs all stocks
Beta
1.07xvs all stocks
50-Day MA
16.29EURUpdated Aug 21, 2026200-Day MA
14.23EURUpdated Aug 21, 2026Avg 10-Day Volume
23.92KSharesUpdated Aug 21, 2026Avg 30-Day Volume
40.54KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.6700EURUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.46Profit Margin: 0.08
Financial Health
Altman Z-Score 5.95: safe zoneNotable
Altman Z-Score: 5.95
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.35B, above the global median of $1.15BNotable
Market cap (USD): 1,350,049,842.711Global Median: 1,146,734,693.424
Revenue is $695.71M, above the global median of $520.53MNotable
Revenue (USD): 695,711,278.979Global Median: 520,528,949.311
Levered free cash flow is $50.72M, above the global median of $16.24MNotable
Levered free cash flow (USD): 50,720,047.621Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedIndustry-Benchmarked Return on Capital Elevated
HBL Engineering Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedIndustry-Benchmarked Return on Capital Elevated
Thyrocare Technologies Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedIndustry-Benchmarked Return on Capital Elevated